Hexis Lab is a technology company working at the forefront of raw material innovation. Hexis Lab produce ground-breaking ethnically targeted skincare products to protect and repair sun-damaged skin and improve life well-being. The company's discovery platform utilizes big data cloud computing approaches and in-silico computer modelling to screen a huge database of natural plant derived compounds for activity against our selected cellular targets.
Syndi is a digital health platform that focuses on enhancing health outcomes through technology and research, initially targeting mental health. The platform employs machine learning and digital phenotyping to provide personalized and immediate care by utilizing moment-by-moment passive smartphone data collection. This approach allows for effective and accessible support tailored to individual needs. Syndi's services aim to improve the treatment of invisible disabilities by facilitating connections between patients and healthcare providers, while also measuring the effectiveness of its applications and digital services. Through its innovative solutions, Syndi seeks to transform the way people access and engage with healthcare.
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
BioStress Lab is revolutionizing the understanding and management of workplace stress. Using discreet biometric devices to objectively monitor workplace stress we make improvements to wellbeing and performance
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Developer of fertility therapy devices designed to provide clinical-standard treatment at home. The company's product contains ovulation assessments, insemination units, pregnant assessments, semen pattern assortment pots, and entry to an application to assist in observing ovulation dates, enabling customers to access affordable fertility treatment in the comfort of their houses.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Developer of a mental health monitoring application designed to understand human behavior. The company's application uses a scientific understanding of human psychology, data science and a proprietary measurement scale (PEBB), enabling users to find the right balance between their inner resources and the demands of their environment and also recognize what energizes them and create lasting wellness changes.
Developer of a mental health monitoring application designed to understand human behavior. The company's application uses a scientific understanding of human psychology, data science and a proprietary measurement scale (PEBB), enabling users to find the right balance between their inner resources and the demands of their environment and also recognize what energizes them and create lasting wellness changes.
4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.
Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.
Decorte Future Industries is an innovative startup focused on developing high-tech, body-adaptive intelligent clothing that integrates biometric sensors and artificial intelligence. This technology aims to enhance human capabilities by enabling intuitive control of robotics through voice, gesture, and touch, while also shifting healthcare from a curative to a preventative model. Their patent-pending body-adaptive exoskeleton allows the clothing to conform to the wearer's body, addressing a significant challenge in the clothing industry. Recently, the company received a competitive Innovate UK grant to leverage its intelligent clothing in combating Covid-19 in care homes. Decorte Future Industries maintains close relationships with the UK Ministry of Defence for research and development, and has garnered support from the Enterprise Europe Network as part of the Horizon 2020 initiative. The team is composed primarily of PhD graduates from the University of Cambridge and includes notable advisors from leading technology and investment firms. Additionally, the company is developing machine-learning technology to extract complex health data from audio, allowing for the collection of critical health metrics using standard microphones.
BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.
Cognitant helps people to better understand their health. We create immersive content, and connect patients to relevant information endorsed by doctors. Our aim is to help doctors and patients make the most of their valuable consultation time.
Directed Systems develops and markets clinical decision support and control systems specifically tailored for anaesthesia, intensive care, and burns centres. The company focuses on creating medical software that facilitates data-driven clinical decisions through clinical optimization applications designed for time-critical conditions. These applications operate using real-time patient monitoring data and include FDA-cleared solutions for cardiovascular management in operating rooms. Directed Systems is also expanding its platform to cover recovery and intensive care settings. By accumulating a vast dataset, the company leverages analytics and AI tools to enhance performance, enabling healthcare professionals to make informed decisions that improve patient outcomes and minimize complications.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Developer of home-monitoring applications designed to measure eyesight. The company's software combines vision science and computer science to measure sight as precisely and reliably as physically possible, enabling patients who are at high risk of eye disease to self-monitor from home and avoid the hospital. .
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
Kheiron Medical Technologies Limited develops Mia, a mammography intelligent assessment tool that helps radiologists to detect breast cancer. Kheiron Medical Technologies Limited was formerly known as Maesterai Limited and changed its name to Kheiron Medical Technologies Limited in June 2016. The company was incorporated in 2016 and is based in London, United Kingdom with an additional location in San Francisco, California.
Astinno operates as a health tech start-up. Astbury’s vision is to change global perceptions of stigmatised health conditions, paving the way for health-tech designed to be seen. Astinno’s first product, currently in development, is called Grace.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Discova is an anonymised, AI-powered mental health and resilience web application sold to corporations and the public sector. Within 5 minutes of sign up, Discova can provide personalised, evidence-based self-help interventions and action plans for the most common mental health problems facing our society. Unlike most solutions in the market that focus only on the problem, Discova predicts the most beneficial support and learning pathway for the individual by understanding the data-driven decisions that drive engagement, motivation, and behaviour change. Currently, there are over 1.9 million combinations that can be made into action plans from our knowledge networks. Through our recommendation engine and algorithms, we can provide the most relevant support for users, so that crisis can be avoided.
The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.
ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.
Appt is making preventive healthcare effortless and accessible. Appt uses behavioural economics and data analytics to increase the uptake of preventive healthcare appointments - earning practices additional income and helping the delivery of nationally set prevention targets. Furthermore, through end-to-end automation of the call and recall process, Appt reduces cumbersome practice workload saving practice staff valuable time.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
Cognetivity Neurosciences Ltd. is a healthcare company based in Vancouver, Canada, that specializes in medical technology focused on cognitive assessment. Established in 2011, the company has developed an integrated cognitive testing platform designed for use in both medical and commercial settings. This platform utilizes artificial intelligence to facilitate the early detection of cognitive impairment, dementia, and Alzheimer's disease. By enabling earlier diagnosis, Cognetivity aims to improve patient outcomes and support better management of cognitive health.
Gendius Ltd. is a UK-based company founded in 2011 by Chris Genders and Rory Cameron, dedicated to improving the management of diabetes. The company has developed Intellin, an app-based platform designed to assist individuals living with diabetes by utilizing their clinical history to identify personal high-risk areas for complications. Intellin focuses users on clinically validated tasks and measures aimed at slowing the progression of these risks. Through its innovative approach, Gendius aims to enhance the quality of life for those affected by diabetes by providing tailored support and guidance.
BrainWaveBank Limited is a brain health research company focused on developing innovative solutions to track and improve cognitive health, particularly in the context of dementia. Founded in 2015 and based in Belfast, United Kingdom, the company has created a unique wearable electroencephalography (EEG) device that allows users to non-invasively measure their brain activity. This device works in conjunction with mobile games designed to challenge cognitive skills, enabling individuals to monitor their cognitive health daily from the comfort of their homes. By securely collecting and analyzing data from a large user base, BrainWaveBank aims to build comprehensive neurocognitive profiles that can advance the understanding of brain health and inform the development of future treatments for neurological disorders. The company's approach emphasizes scalability and accessibility, making it a valuable tool for both consumers and clinical professionals.
Echopoint Medical Ltd is a medical device company based in London, United Kingdom, focused on developing optical-fibre based sensors for use in minimally invasive procedures, particularly in the field of cardiology. Founded in 2018 as a spin-out from University College London, the company aims to enhance precision in the diagnosis and treatment of cardiovascular diseases. By leveraging advancements in fibre optic sensor technology, Echopoint Medical seeks to address significant unmet needs within healthcare, providing devices that offer exceptional sensing and imaging capabilities. These innovations are designed to improve patient outcomes while reducing costs and complications associated with cardiac surgeries.
Px HealthCare (Px) has developed the only validated, personalised medical support platform for cancer patients, called OWise, which has been demonstrated to improve the patient – physician relationship and is designed to improve users quality of life and even survival. Originally developed in the Netherlands, the award-winning mobile app ‘OWise breast cancer’ has been independently studied, revealing that 90% of the patients and 90% of the treating clinicians recommend OWise to breast cancer patients. With the widespread use of smartphones, OWise is designed to support patients as part of their everyday life during treatment. NHS England has selected OWise to be part of its Innovation Accelerator (2015) and it was listed in the Top25 of all health apps (by IQVIA, 2017). The focus is currently on breast cancer as so many women are affected by the condition and the impact, both mentally and physically, is big. Through the website (www.owise.nl / www.owise.eu) and the OWise smartphone app, Px HealthCare offers women (and men) smart internet tools which helps them gaining insight into and control over their situation during and after illness. Px HealthCare is a life sciences company, founded in 2012.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Healum is a developer of connected software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company's AI-powered platform offers personalized care and support by leveraging data-driven insights and evidence-based behavioral interventions. This approach not only helps patients monitor their physical and mental health effectively but also empowers healthcare professionals to provide tailored assistance. By focusing on customized interventions, Healum seeks to motivate patients in managing their chronic health issues more efficiently and cost-effectively.
Verdel Instruments Ltd specializes in the development of two-dimensional mass spectrometry (2DMS) technology, focusing on equipment for structural analysis and sequencing. Established in 2018 and located in Coventry, United Kingdom, the company provides advanced mass spectrometry solutions utilized in analytical laboratories. These solutions enable the identification of key components and impurities across various sectors, including biopharmaceuticals, food, chemical products, and environmental analysis. By allowing researchers to obtain structural information from complex mixtures, Verdel Instruments plays a crucial role in enhancing the accuracy and efficiency of analytical processes.
Feebris Ltd is a technology company founded in 2017 and based in Saffron Walden, United Kingdom. The company specializes in developing artificial intelligence and machine learning algorithms aimed at the detection of respiratory conditions. Its platform integrates with various point-of-care devices, such as digital stethoscopes and wearables, to facilitate community-based diagnosis and monitoring. By leveraging its AI-driven software, Feebris enables non-clinical users to identify clinical deterioration early, thereby helping to prevent complications and reduce hospitalizations. The team at Feebris combines expertise in biomedical engineering, machine learning, and global health, all driven by a commitment to transforming healthcare into a more equitable, personalized, and patient-centered system.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Our mission is to transform how decisions are made about our health. Decisions informed by patient outcomes, and shared by patient and clinician. Shared decisions, digital consent, better outcomes. Our digital consent platform uses data to inform and design to simplify complexity. Secure, auditable, and a great experience for all our users.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
COHESION Medical Ltd. is a Connected Citizen Health company building the safest, smartest and most streamlined health system in the world, improving global population health and wellness. COHESION.OS is making citizens more empowered, services more efficient and sciences more innovative.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. By utilizing an intelligent agent, Mendelian analyzes patients' clinical features to identify the genes responsible for rare conditions. Physicians input phenotypic details, and the platform generates outputs that indicate potential causative genes and mutations. This innovative approach enhances the investigation of undiagnosed cases, allowing for earlier detection and treatment of rare diseases through machine learning and knowledge reasoning.
MediSieve Ltd. is a London-based medical device company that specializes in developing Magnetic Blood Filtration (MBF) technology for the treatment of blood-borne diseases. The company’s innovative device employs a magnetic filter to remove infected blood cells, making it applicable for conditions such as malaria, leukemia, and sepsis. MediSieve’s system operates by circulating a patient’s blood through an external loop, where targeted magnetic particles bind to specific disease-related targets. The blood is then filtered through a magnetic device that captures these particles and their attached targets, allowing the remainder of the blood to return to the patient without contamination. Founded in 2014 and located at the Imperial Incubator in White City, London, MediSieve has dedicated facilities for product development and validation, including capabilities for various blood testing methods.
PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.
Vitaccess is a multi award-winning digital-health and strategic consultancy, founded in 2017. Though based in Oxford, UK, their reach is truly global. They offer a world-class real-world evidence (RWE) data portfolio and data science research via MyRealWorld™, their state-of-the-art digital platform, and experience-based Market Access and Health Economics and Outcomes Research (HEOR) solutions. Their heritage in HEOR and Market Access makes us a trusted partner to the pharmaceutical industry. They understand the importance of scientific rigor in RWE studies, as well as the complexities of information governance - including GDPR and HIPAA. Industry standards have been applied to the creation of their pioneering and flexible digital platform, MyRealWorld™, through which they capture RWE in real-time, to be transmitted in aggregated, anonymized form to customizable and interactive research dashboards.
COHESION Medical Ltd. is a Connected Citizen Health company building the safest, smartest and most streamlined health system in the world, improving global population health and wellness. COHESION.OS is making citizens more empowered, services more efficient and sciences more innovative.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
BIOS Health is a company based in Cambridge, United Kingdom, that specializes in developing a neural interface platform aimed at treating chronic health conditions. Founded in 2015, BIOS integrates advances in hardware, big data, and machine learning to create solutions that decode and encode neural signals from the body. The company also focuses on the development of prosthetic connectors, which standardize the connection between bionic devices and the body’s neural and soft-tissue systems. These implanted medical devices are designed to link nerve activity to specific conditions, facilitating precise communication and control for patients using prosthetics. BIOS operates an additional research and development office in Montreal, Canada.
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.
Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol.
PulmonIR is focused on the research and development of innovative medical devices aimed at detecting and monitoring lung diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer. The company's technology is designed to assist healthcare professionals in diagnosing COPD patients more efficiently, allowing for quicker and safer treatment options for those suffering from these conditions. By streamlining the testing process, PulmonIR aims to improve patient outcomes and enhance the overall management of lung diseases.
Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry.
Service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.
BioSystems Technology engages in the development of alternative research models. BioSystems Technology was founded by an infectious disease research fellow and a Professor of Molecular Pathogenicity based at the University of Exeter.
MyWay Digital Health is a comprehensive online self management platform. Improving the lives of people living with long-term conditions around the globe through data-driven technology solutions.
MIOTIFY Ltd. develops software and online toolkit to boost the quality of digital health applications. The company's system allows both developers and non-IT staff to create applications within a guided framework to help them build in quality from the start and auto-generate evidence to include in a submission for regulatory approval. MIOTIFY Ltd. provides new data to enable medics to monitor patients remotely and gather insights to inform their treatment. MIOTIFY Ltd. was incorporated in 2015 and is based in Windsor, United Kingdom.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on enhancing access to blood tests through innovative healthcare devices. Founded in 2014, Entia offers two primary products: Aptus, a device for testing haemoglobin and haematocrit levels, and Affinity, designed for cancer patients to monitor their blood counts from home. These devices facilitate health screening, blood donor screening, maternal and child health, nutrition, and sports applications, while also enabling cancer patients to manage their health more effectively, reducing the risk of infection and minimizing hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, and business development, all aimed at improving patients' quality of life by allowing them to conduct essential health monitoring from the comfort of their homes.
Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring small amounts of substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, allowing for immediate testing in urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and formerly known as UroSens Ltd., the company is headquartered in Sunderland, United Kingdom, and is committed to improving cancer detection and monitoring to enhance patient outcomes.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
BrainWaveBank Limited is a brain health research company focused on developing innovative solutions to track and improve cognitive health, particularly in the context of dementia. Founded in 2015 and based in Belfast, United Kingdom, the company has created a unique wearable electroencephalography (EEG) device that allows users to non-invasively measure their brain activity. This device works in conjunction with mobile games designed to challenge cognitive skills, enabling individuals to monitor their cognitive health daily from the comfort of their homes. By securely collecting and analyzing data from a large user base, BrainWaveBank aims to build comprehensive neurocognitive profiles that can advance the understanding of brain health and inform the development of future treatments for neurological disorders. The company's approach emphasizes scalability and accessibility, making it a valuable tool for both consumers and clinical professionals.
Azul Optics is developing a device that can rapidly assess macular pigment density. Their device will be affordable, fast, easy-to-use and compact, making it easy to integrate macular pigment density screening into regular eye exams.
Their goal is to introduce a technology that enables eye health professionals to rapidly assess macular pigments as an indicator of eye health.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DynamX Medical specializes in the development of a cost-effective and reliable precancer screening system designed for rapid tissue biopsy analysis. This innovative technology enables point-of-care operation, allowing nurses to efficiently conduct screenings in various clinical settings. The company's focus on creating accessible diagnostic tools aims to enhance the identification of healthy and benign tissue specimens, ultimately improving patient care and outcomes. Established in London, United Kingdom, DynamX Medical has positioned itself at the forefront of advancements in medical diagnostics since its inception.
Isansys Lifecare is a new generation medical device and healthcare information company.
Sarissa Biomedical, Ltd. specializes in the development and production of advanced biosensors aimed at measuring neuroactive chemicals in both in vitro and in vivo environments for research and clinical diagnostics. Founded in 2002 and based in Coventry, United Kingdom, the company offers a range of minimally invasive microelectrode electrochemical sensors that provide high sensitivity and accuracy for detecting purines and other neurochemicals. These sensors serve as important indicators of neurological activity and disorders. Sarissa Biomedical markets its products in various regions, including the United Kingdom, the United States, Canada, and Japan, contributing to advancements in the understanding and diagnosis of neurological conditions.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.